Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.
Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the new era of treatment for patients with acute myeloid leukemia (AML) afterthe approval of 3 new treatment regimensat the end of 2018.
With these approvals, physicians are questioning how necessary the standard backbone chemotherapy low-dose cytarabine and anthracycline-based treatments are; these agents have been the standard since the 1970s for younger and fitter patients.
For the last few years, physicians have been using low-dose hypomethylating agents for older patients. In the last year, there has been a breakthrough in terms of combination therapy with low-dose chemotherapy and oral agents.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More